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There is increasing concern that the uptake of peritoneal dialy-
sis (PD) is decreasing, especially in Europe, where there is also
substantial variation in PD prevalence and occurrence [1]. In
an interesting contribution to this issue of Nephrology Dialysis
Transplantation, Boyer et al. [2] report how the introduction of
an assisted PD programme positively influenced the uptake of
PD and counterbalanced the decline in its occurrence over the
last decade due to a variety of reasons. Of the patients included,
~20% died during the observation period and a comparable
number changed to in-centre haemodialysis (HD), leaving two
of three patients on PD. Half of those remaining on PD became
independent in their PD-related care.
The mean age and number of comorbidities of the patient
population with end-stage kidney disease have increased over
recent decades. Therefore, at first glance, home-based therapies
may not seem to be a straightforward option for such patients
and many physicians do not offer PD in this setting [3].
However, their frailty also means that patients in this group
might benefit most from spending more time in their home en-
vironment, avoiding the burden of thrice-weekly transfer to a
dialysis unit and post-dialysis hangover. Thus, assisted PD
might also be useful to increase PD use in frail and comorbid
patients [4]. Some groups advocate the use of (assisted) PD as a
kind of transition between full and conservative care, allowing
treatment to be tailored to the specific needs of the patient at
specific moments in time, and the focus to be on quality of life
rather than biochemical surrogates [5, 6]. Most of the obstacles
to home-based treatment for this frail population can be readily
overcome by providing assistance for the performance of PD.
Hence the concept of assisted PDmakes sense.
Boyer et al. [2] conclude that implementation of an assisted
PD programme might be a way to tackle the declining uptake of
PD in Europe. Whereas this statement is generally likely to be
true, some unanswered questions remain. In their study, posi-
tive change was most pronounced in the years immediately af-
ter the start of the programme [2], suggesting that a pre-
existing pool of potential assisted PD candidates was drained.
Thus the real long-term impact might be smaller than that ob-
served. Assisted PD can potentially prolong the success of PD
as a technique, as demonstrated by the fact that two of three
patients remained on PD. Other reports have also observed that
increasing the occurrence of PD does not jeopardize the techni-
que’s success and contributes to greater PD use [7–9]. However,
as overall survival is lower in this patient group, often accompa-
nied by extensive comorbidity and frailty, the impact of assisted
PD on PD prevalence might be less than hoped for.
Other important questions about the impact of assisted PD
on PD occurrence and prevalence include: (i) can the success of
this initiative be generalized to other settings, (ii) is assisted PD
a panacea to increase PD use and (iii) is it really relevant and
necessary to augment the incidence or prevalence of PD?
There are several reasons why the findings of Boyer et al. [2]
might not be generalizable to other settings. The initiative to in-
crease the occurrence of PD by creating a programme for assis-
ted PD was set in a single centre, where a strong focus on PD
already existed and PD prevalence was already above the aver-
age of most regions in Europe. Patient uptake of assisted PD
varies between centres, even when it is universally available [4].
It is likely that the reasons that make overall PD prevalence
lower in some centres are exactly the same as those that explain
why some centres would not be willing to or would not be
successful in implementing an assisted PD programme [10].
The organization of healthcare in the UK and the associated re-
imbursement system might also have an impact [11, 12]. Public,
not-for-profit centres might find it easier to rearrange their
budgets so that assisted PD programmes could be supported in
a structured way. In France, sufficient reimbursement has been
foreseen for (private) district nurses, avoiding financial disincen-
tives for assisted PD. In settings where reimbursement by the
healthcare payer is insufficient for assisted PD, it would be diffi-
cult to implement it, as neither nephrologists, the dialysis unit
nor the patients would want to suffer financial penalties.
Assisted care can be organized in different ways [6] regard-
ing the type of modality supported [ambulatory PD or continu-
ous ambulatory PD (CAPD) or both], the type and extent of
assistance provided (only logistical help, only nursing care and
supervision, the actual connection of the patient to the bag or
cycler or a combination of these) and the types of healthcare
workers involved. In the study by Boyer et al. [2], assistance was
only provided by healthcare assistants for practical issues, such
as building up the cycler machine and transporting bags into
the house, but not for the actual connection of the patient to the
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machine; in addition, there was no option for assisted CAPD.
As such, this form of assisted PD would be unsuitable for
patients with visual, dexterity or coordination problems. It also
presumes that the patient is able to manage a cycler alone dur-
ing the night. This setup might thus have a negative impact on
the number of potentially eligible patients and greater gains
could be expected in settings where more extensive assistance is
provided. However, more extensive help regarding the type of
healthcare worker and the amount of time involved would in-
crease the cost of assisted PD, possibly up to the level of in-cen-
tre HD. The success of the technique might also be different in
a population of patients unable to connect themselves, as
comorbidities would likely be higher. The willingness of
patients to accept assisted PD and of staff to perform it depends
upon the balance between expected and provided service. This
balance is partially influenced by reimbursement and a willing-
ness to put patient comfort first.
The second question is even more relevant: is introducing
assisted PD a sufficient measure to increase PD uptake? In the
previous paragraph, we indicated that the willingness and ca-
pacity to implement assisted PD is probably linked to the will-
ingness and capacity to perform PD in general [10]. Thus we
need to explore the true reasons why PD uptake might remain
below expected levels in Europe (Figure 1). During several re-
cent focus groups, a EuroPD-led group of PD enthusiasts iden-
tified potential barriers to PD growth. More specifically, they
identified the potential interconnections between these barriers,
indicating that it is unlikely that a single intervention will be
sufficient for change. Further discussion is ongoing and results
will be presented during the International Society for Peritoneal
Dialysis/EuroPD meeting in Glasgow in May 2020. It is hard to
accept that these barriers are based on differences in medical
outcomes, as most studies indicate that outcomes of patients on
PD and HD are comparable, especially in the first few years af-
ter starting treatment [13]. Even differences in case mix cannot
explain regional differences in PD uptake, as similar outcomes
for patients on PD versus HD remain after stratification for the
most important comorbidities [13]. Some have formulated a
hypothesis that financial incentives might play a role [14]. For
example, uptake of PD has surged in the USA after a change in
the reimbursement system in favour of PD, but uptake still
remains lower than expected, at ~10% [15]. In many other
countries, such as Germany and Belgium, increasing reimburse-
ment for PD did not result in increased uptake of PD [16]. Of
note, to improve PD occurrence and prevalence, Kaiser
Permanente started a multidisciplinary PD initiative that in-
cluded patient and caregiver education, education and support
tools for healthcare professionals, streamlined system-level pro-
cesses, monitoring and continuous quality improvement [8]. As
a result, PD occurrence increased from 15.2% in 2008 to 33.8%
in 2018 where this initiative was in place, and contrasts with the
rather small increase observed in the rest of the USA. While it
FIGURE 1: Barriers and obstacles to increasing PD use reported as unidimensional barriers, aggregated into categories, show underlying
common hidden drivers for low PD use.
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can be debated whether the motivation for this initiative is
driven by underlying financial motives, it does at least indicate
that improving reimbursement per se is not sufficient to in-
crease PD use. Willingness, a holistic vision and the right orga-
nizational structure are also needed, as are present in a large
integrated healthcare system such as Kaiser Permanente. It is
often claimed that PD is cheaper than HD; however, this state-
ment is strongly dependent on the organization of care and lo-
gistics. Some countries, like Hong Kong and Taiwan, have
introduced a PD-first policy, as in their settings it is a reason-
able approach to ensure that renal replacement therapy is avail-
able to as many people who need it as possible. However, there
is no clear relationship between the differing costs of HD versus
PD and the prevalence of PD patients [12]. Thus, developing a
PD-friendly ‘policy’ and creating ‘commitment’ seems to be
more important than financial arrangements [17]. The observa-
tion that >80% of patients who initiated PD in the Kaiser
Permanente programme were still on PD 1 year after initiation,
with a stable mortality rate similar to that of patients on HD
[8], fits reports from other groups who have successfully in-
creased PD occurrence [2, 7, 9]. This undermines the excuse of
many centres that they do not have the right patient mix and
that forcing patients to undergo PD would result in a surge in
technique failure [18].
Other hurdles that pop up regularly are centre size, the prob-
lem of late referral and the management of peritoneal access.
Smaller centres seem to have greater technique failure and
lower PD occurrence rates. In the Initiative for Patient
Outcomes in Dialysis-PD study, both centre size and the pro-
portion of patients on PD/HD were associated with technique
success [19]. This illustrates the point that next to experience, a
commitment to PD is essential to successfully increase its up-
take. Centre size might also be directly linked to the two other
barriers. It is conceivable that in small centres, there is less ex-
pertise in managing PD catheter problems and that, as a conse-
quence, there are fewer sufficiently skilled personnel to provide
acute PD access for late referrals on a 24/7 basis. As for assisted
PD, the creation of a dedicated programme for late referrals
[20, 21] and the option of PD catheters being inserted at the
bedside by a nephrologist [22] have both been demonstrated to
increase PD occurrence and prevalence. However, as for assis-
ted PD, the fact that some centres develop such urgent start
programmes is a token of their commitment to offer PD to as
many patients as possible, and it remains uncertain whether
forcing centres to develop such programmes would actually be
effective. In addition, the problems of late referral and catheter
placement are indirectly linked, as described below.
Last but not least, is it reasonable for a ‘increase in PD up-
take’ to be seen as a relevant goal or quality indicator by itself?
In the interests of shared decision-making [23], what is truly
important is that patients have free choice regarding
their treatment modality. The first prerequisite for this is that
all modalities are available and can be chosen. Thus it is neces-
sary that centres offer PD in all its different formats. Expanding
the range of available options, for example, by introducing
assisted PD, will allow more people to choose the option that
best fits their preferences, expectations and needs.
It is also essential that there is sufficient experience with all
different modalities to ensure truly free choice. Thus the second
prerequisite is that patients are ‘informed’ in an objective
way about the different modalities available. A dedicated pre-
dialysis or low-clearance clinic that works smoothly is essential
to ensure that patients receive information in a structured, bal-
anced way that helps them make the right decision [24]. There
is evidence that the quality of educational material and assis-
tance provided for decision-making is often suboptimal [25],
and most surveys have revealed that a substantial proportion of
patients do not remember having been informed about the dif-
ferent options available [26]. Some interesting initiatives for im-
provement have been undertaken [27]. Healthcare workers
themselves need to be confident that they can manage different
therapies for individual patients. Such confidence most likely
depends upon adequate formal training and education [28] on
the one hand and clinical experience on the other. For many
healthcare workers, these prerequisites are fulfilled in a subopti-
mal way [28]. Training in PD is, for most trainees in nephrol-
ogy, limited in scope and time, which makes them less
confident regarding the management of more complex patients
[29] and increases the tendency to solve PD-related problems
by transferring patients to HD. In small centres, exposure to PD
patients is low, so there is limited opportunity to increase one’s
own experience or ask advice from someone else. In this way, a
vicious downward spiral is created. Collaboration protocols be-
tween centres might be a good solution here, but this might
prove difficult in a setting of privatized healthcare.
In conclusion, the decreasing trend of PD in Europe is of
concern, not because of PD per se, but because it is an indicator
of two worrying underlying factors. First is the fact that patients
still do not have true free choice regarding renal replacement
therapy that suits their preferences and expectations and which
they can fit around their lives. Second, some healthcare organi-
zations and nephrology units remain reluctant to provide truly
patient-centred care. A culture of placing patient preference
and quality of life first should be fostered if we truly want to im-
prove patient care. In centres with such a culture, additional
modalities such as assisted PD can open up the options for
patients, even when they have serious comorbidities. In centres
that only pay lip service to such patient-centred care, it is un-
likely that assisted PD programmes will thrive. Programmes
promoting home-based therapies can only be successful if they
are accompanied by a true shift in mentality. Some of the meas-
ures suggested in this editorial are neither difficult nor costly to
implement, provided one is willing to seek out and address the
true underlying barriers.
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